MedTrace Logo

Can COX-2 Inhibitor Decrease Stricture Recurrence After Direct Vision Internal Urethrotomy?

NCT06697106 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2024-11-21

No results posted yet for this study

Summary

To evaluate the efficacy and safety of nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing urethral stricture recurrence after direct visual internal urethrotomy.

Conditions

  • COX-2 Inhibitor
  • Meloxicam
  • Stricture Recurrence
  • Direct Vision Internal Urethrotomy

Interventions

DRUG

Nonsteroidal anti-inflammatory drugs

Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.

DRUG

Placebo

Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.

Sponsors & Collaborators

  • New Valley University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-20
Primary Completion
2025-04-01
Completion
2025-04-01

Countries

  • Egypt

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06697106 on ClinicalTrials.gov